Resolvin E1 and chemokine-like receptor 1 mediate bone preservation

Journal of Immunology

Volumn 190, Issue 2, 2013, Pages 689-694

  Gao, Li ^a,d   Faibish, Dan ^a,b   Fredman, Gabrielle ^a,e   Herrera, Bruno S ^b   Chiang, Nan ^c   Serhan, Charles N ^c   Van Dyke, Thomas E ^b   Gyurko, Robert ^a  

^a BOSTON UNIVERSITY   (United States)

^b FORSYTH INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING METABOLISM; ALKALINE PHOSPHATASE; BONE SIALOPROTEIN; CHEMOKINE LIKE RECEPTOR 1; OSTEOPROTEGERIN; RECEPTOR PROTEIN; RESOLVIN E1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEFECT; BONE METABOLISM; BONE REGENERATION; BONE REMODELING; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ALVEOLAR BONE LOSS; ANIMALS; BONE AND BONES; CELL LINE; EICOSAPENTAENOIC ACID; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; LEUKOCYTES; MALE; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; PERIODONTITIS; PERITONEAL CAVITY; RECEPTORS, CHEMOKINE; WOUND HEALING;

EID: 84872179280     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103688     Document Type: Article

References (40)

1. Gilroy, D. W., T. Lawrence, M. Perretti, and A. G. Rossi. 2004. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3: 401-416.
2. Serhan, C. N., N. Chiang, and T. E. Van Dyke. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8: 349-361.
3. Serhan, C. N., C. B. Clish, J. Brannon, S. P. Colgan, N. Chiang, and K. Gronert. 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192: 1197-1204.
4. Arita, M., F. Bianchini, J. Aliberti, A. Sher, N. Chiang, S. Hong, R. Yang, N. A. Petasis, and C. N. Serhan. 2005. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201: 713-722.
5. Oh, S. F., P. S. Pillai, A. Recchiuti, R. Yang, and C. N. Serhan. 2011. Proresolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121: 569-581.
6. Hasturk, H., A. Kantarci, T. Ohira, M. Arita, N. Ebrahimi, N. Chiang, N. A. Petasis, B. D. Levy, C. N. Serhan, and T. E. Van Dyke. 2006. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J. 20: 401-403.
7. Hasturk, H., A. Kantarci, E. Goguet-Surmenian, A. Blackwood, C. Andry, C. N. Serhan, and T. E. Van Dyke. 2007. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179: 7021-7029.
8. Samson, M., A. L. Edinger, P. Stordeur, J. Rucker, V. Verhasselt, M. Sharron, C. Govaerts, C. Mollereau, G. Vassart, R. W. Doms, and M. Parmentier. 1998. ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur. J. Immunol. 28: 1689-1700.
9. Wittamer, V., J. D. Franssen, M. Vulcano, J. F. Mirjolet, E. Le Poul, I. Migeotte, S. Brézillon, R. Tyldesley, C. Blanpain, M. Detheux, et al. 2003. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198: 977-985.
10. Muruganandan, S., A. A. Roman, and C. J. Sinal. 2010. Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J. Bone Miner. Res. 25: 222-234.
11. Methner, A., G. Hermey, B. Schinke, and I. Hermans-Borgmeyer. 1997. A novel G protein-coupled receptor with homology to neuropeptide and chemoattractant receptors expressed during bone development. Biochem. Biophys. Res. Commun. 233: 336-342.
12. Poulsen, R. C., K. H. Gotlinger, C. N. Serhan, and M. C. Kruger. 2008. Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake. Am. J. Hematol. 83: 437-445.
13. Herrera, B. S., T. Ohira, L. Gao, K. Omori, R. Yang, M. Zhu, M. N. Muscara, C. N. Serhan, T. E. Van Dyke, and R. Gyurko. 2008. An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br. J. Pharmacol. 155: 1214-1223.
14. Gyurko, R., C. C. Siqueira, N. Caldon, L. Gao, A. Kantarci, and T. E. Van Dyke. 2006. Chronic hyperglycemia predisposes to exaggerated inflammatory response and leukocyte dysfunction in Akita mice. J. Immunol. 177: 7250-7256.
15. Graves, D. T., D. Fine, Y. T. Teng, T. E. Van Dyke, and G. Hajishengallis. 2008. The use of rodent models to investigate host-bacteria interactions related to periodontal diseases. J. Clin. Periodontol. 35: 89-105.
16. McCarthy, T. L., M. Centrella, and E. Canalis. 1988. Further biochemical and molecular characterization of primary rat parietal bone cell cultures. J. Bone Miner. Res. 3: 401-408.
17. Bannenberg, G. L., N. Chiang, A. Ariel, M. Arita, E. Tjonahen, K. H. Gotlinger, S. Hong, and C. N. Serhan. 2005. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174: 4345-4355.
18. Mas, E., K. D. Croft, P. Zahra, A. Barden, and T. A. Mori. 2012. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 58: 1476-1484.
19. Shimizu, T. 2009. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 49: 123-150.
20. Schwab, J. M., N. Chiang, M. Arita, and C. N. Serhan. 2007. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
21. Arita, M., M. Yoshida, S. Hong, E. Tjonahen, J. N. Glickman, N. A. Petasis, R. S. Blumberg, and C. N. Serhan. 2005. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 102: 7671-7676.
22. Bondue, B., V. Wittamer, and M. Parmentier. 2011. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev. 22: 331-338.
23. Navarro-Xavier, R. A., J. Newson, V. L. Silveira, S. N. Farrow, D. W. Gilroy, and J. Bystrom. 2010. A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J. Immunol. 184: 1516-1525.
24. Ohira, T., M. Arita, K. Omori, A. Recchiuti, T. E. Van Dyke, and C. N. Serhan. 2010. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J. Biol. Chem. 285: 3451-3461.
25. Berg, V., B. Sveinbjörnsson, S. Bendiksen, J. Brox, K. Meknas, and Y. Figenschau. 2010. Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157). Arthritis Res. Ther. 12: R228.
26. Taubman, M. A., P. Valverde, X. Han, and T. Kawai. 2005. Immune response: the key to bone resorption in periodontal disease. J. Periodontol. 76(11, Suppl): 2033-2041.
27. Graves, D. T., T. Oates, and G. P. Garlet. 2011. Review of osteoimmunology and the host response in endodontic and periodontal lesions. J. Oral. Microbiol. 3.
28. Van Dyke, T. E. 2011. Proresolving lipid mediators: potential for prevention and treatment of periodontitis. J. Clin. Periodontol. 38(Suppl 11): 119-125.
29. Hoemann, C. D., H. El-Gabalawy, and M. D. McKee. 2009. In vitro osteogenesis assays: influence of the primary cell source on alkaline phosphatase activity and mineralization. Pathol. Biol. (Paris) 57: 318-323.
30. Boyle, W. J., W. S. Simonet, and D. L. Lacey. 2003. Osteoclast differentiation and activation. Nature 423: 337-342.
31. Belibasakis, G. N., and N. Bostanci. 2012. The RANKL-OPG system in clinical periodontology. J. Clin. Periodontol. 39: 239-248.
32. Wang, D., K. Christensen, K. Chawla, G. Xiao, P. H. Krebsbach, and R. T. Franceschi. 1999. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J. Bone Miner. Res. 14: 893-903.
33. Quarles, L. D., D. A. Yohay, L. W. Lever, R. Caton, and R. J. Wenstrup. 1992. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J. Bone Miner. Res. 7: 683-692.
34. Redlich, K., and J. S. Smolen. 2012. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat. Rev. Drug Discov. 11: 234-250.
35. Walsh, N. C., T. N. Crotti, S. R. Goldring, and E. M. Gravallese. 2005. Rheumatic diseases: the effects of inflammation on bone. Immunol. Rev. 208: 228-251.
36. Raisz, L. G. 2005. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115: 3318-3325.
37. Watkins, B. A., Y. Li, and M. F. Seifert. 2001. Nutraceutical fatty acids as biochemical and molecular modulators of skeletal biology. J. Am. Coll. Nutr. 20: 410S-416S; discussion 417S-420S.
38. Traianedes, K., M. R. Dallas, I. R. Garrett, G. R. Mundy, and L. F. Bonewald. 1998. 5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology 139: 3178-3184.
39. Connor, K. M., J. P. SanGiovanni, C. Lofqvist, C. M. Aderman, J. Chen, A. Higuchi, S. Hong, E. A. Pravda, S. Majchrzak, D. Carper, et al. 2007. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13: 868-873.
40. Kim, T. H., G. D. Kim, Y. H. Jin, Y. S. Park, and C. S. Park. 2012. Omega-3 fatty acid-derived mediator, Resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int. Immunopharmacol. 14: 384-391.